Intas Pharmaceuticals Limited Imatinib Export Data — India (DGFT 2022–2026)

Name: Intas Pharmaceuticals Limited Imatinib Export Records India — #6 Exporter, 19 Shipments, $857.6K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-04-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Imatinib

India Pharmaceutical Trade Intelligence

$29.3M224 Suppliers119 CountriesHS 30049049

ExportsIndia → UNITED STATES24.3%India → BELGIUM12.4%

ImportsGERMANY → India$331.7M UNITED STATES → India$584.7K

#1 Supplier: CIPLA LIMITED #1 Buyer: H.ESSERS &

Intas Pharmaceuticals Limited — Imatinib Exporter #6 | $857.6K Trade Value | TransData Nexus | TransData Nexus

Intas Pharmaceuticals Limited — Imatinib Exporter Profile

Indian Pharmaceutical Exporter · #6 for Imatinib · $857.6K export value · DGFT Verified

Intas Pharmaceuticals Limited is the #6 Indian exporter of Imatinib with $857.6K in export value and 19 verified shipments. Intas Pharmaceuticals Limited holds a 2.9% market share in Imatinib exports across 6 countries. The company exports 75 pharmaceutical products worth $372.3M across 19 therapeutic categories.

Intas Pharmaceuticals Limited — Imatinib Export Profile: Buyers & Destinations

Intas Pharmaceuticals Limited Imatinib export treemap — buyers and destination countries | TransData Nexus

Where Does Intas Pharmaceuticals Limited Export Imatinib?

Country	Value	Shipments	Share
SPAIN	$250.0K	5	44.5%
NETHERLANDS	$145.3K	5	25.8%
UNITED KINGDOM	$100.0K	2	17.8%
POLAND	$56.5K	2	10.0%
FRANCE

Who Are the Top Buyers of Imatinib from Intas Pharmaceuticals Limited?

Buyer	Country	Value	Orders
ACCORD HEALTHCARE SLU	SPAIN	$150.0K	3
ACCORD HEALTHCARE B V	NETHERLANDS	$110.8K	4
XXCORXXHEAXXHCAXX SXX	SPAIN	$100.0K	2
XXCORXXHEAXXHCAXX LTXX	MALTA	$50.9K	7
ACCORD HEALTHCARE LIMITED	MALTA	$50.6K	4
XXCORXXHEAXXHCAXX POXXKA XX ZXX O	POLAND	$50.0K	1
XXCORXXNL XX XXB	NETHERLANDS	$34.4K	1
XXCORXXHEAXXHCAXX B XX	FRANCE	$8.1K	1
ACCORD HEALTHCARE POLSKA SP Z O O	POLAND	$6.5K	1
ACCORD HEALTHCARE LTD	MALTA	$595	2

Intas Pharmaceuticals Limited supplies Imatinib to 11 buyers globally. The largest buyer is ACCORD HEALTHCARE SLU (SPAIN), followed by ACCORD HEALTHCARE B V (NETHERLANDS) and XXCORXXHEAXXHCAXX SXX (SPAIN). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.

What Imatinib Formulations Does Intas Pharmaceuticals Limited Export?

Product Description / Formulation	Value	Shipments
IMATINIB 400MG 3X10T ALU ACCORD-PP-ES	$100.0K	2
IMATINIB 100MG 6X10T ALU ACCORD-PP-FR	$58.4K	4
IMATINIB 100MG 6X10T ALU (ACCORD-PP-FR	$50.4K	3
IMATINIB 400MG 3X10T ALU (ACCORD-PP-CZ	$50.1K	2
IMATINIB400MG 3X10T ALU ACCORD-PP-FISE	$50.0K	1
IMATINIB400MG 3X10T ALU ACCORD-PP-DE	$50.0K	1
IMATINIB 400MG 3X10T ALU (ACCORD-PP-ES	$50.0K	1
IMATINIB 100MG 6X10T ALU ACO-PP-UK	$50.0K	1
IMATINIB 100MG 6X10T ALU (ACO-PP-UK	$50.0K	1
IMATINIB 400MG 3X10T ALU (ACCORD-PP-IE	$34.6K	2

Intas Pharmaceuticals Limited exports 18 distinct Imatinib formulations including tablets, capsules, syrups, and combination drugs. The top formulation is IMATINIB 400MG 3X10T ALU ACCORD-PP-ES with 2 shipments worth $100.0K.

How Does Intas Pharmaceuticals Limited Compare to Nearest Imatinib Exporters?

Exporters ranked immediately above and below #6 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
4	JODAS EXPOIM PRIVATE LIMITED	$1.9M	38	3	$50.0K
5	NATCO PHARMA LIMITED	$1.3M	33	9	$39.7K
6	INTAS PHARMACEUTICALS LIMITED ★	$857.6K	19	6	$45.1K
7	ACCURE LABS PRIVATE LIMITED	$629.7K	20	2	$31.5K
8	HETERO LABS LIMITED	$291.4K	10	2	$29.1K

Intas Pharmaceuticals Limited ranks #6 among 224 Indian Imatinib exporters. Average shipment value of $45.1K compared to the market average of $82.5K. The closest competitors by value are JODAS EXPOIM PRIVATE LIMITED and NATCO PHARMA LIMITED.

Which Indian Ports Ship Imatinib Exports?

Port	Shipments	% Share
SAHAR AIR	314	18.2%
SAHAR AIR CARGO ACC (INBOM4)	301	17.4%
DELHI AIR CARGO ACC (INDEL4)	235	13.6%
DELHI AIR	142	8.2%
Bombay Air	123	7.1%
HYDERABAD AIR	69	4.0%
HYDERABAD ACC (INHYD4)	61	3.5%
AHEMDABAD AIR	35	2.0%

Geopolitical & Trade Policy Impact on Intas Pharmaceuticals Limited's Imatinib Exports

The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Intas Pharmaceuticals. The Israel-Iran tensions have led to increased security risks in the Strait of Hormuz and the Red Sea–Suez Canal corridor, prompting major carriers to reroute shipments around the Cape of Good Hope. This detour has extended transit times by 10–20 days and raised freight rates by 40–50% on key India–Europe routes, impacting the cost-effectiveness and timeliness of exports. (livemint.com)

Conversely, the ongoing US-China trade tensions have opened avenues for Indian pharmaceutical companies to capture a larger share of the U.S. market. Intas's acquisition of UDENYCA® and the FDA's acceptance of its biosimilar applications position the company to leverage these opportunities effectively. However, compliance with the European Union's Falsified Medicines Directive (FMD) remains a critical factor for market access. Intas's proactive approach in securing partnerships and ensuring regulatory compliance underscores its commitment to maintaining and expanding its presence in the European market.

Intas Pharmaceuticals Limited — Regulatory Compliance & Quality Standards

Maintaining stringent regulatory compliance is paramount for Indian pharmaceutical exporters. Intas Pharmaceuticals has demonstrated a strong commitment to adhering to international quality standards, as evidenced by its successful acquisitions and partnerships that necessitate compliance with FDA, WHO, and EU Good Manufacturing Practices (GMP). The company's proactive engagement in regulatory processes, such as the FDA's acceptance of its Biologics License Application for DMB-3115, reflects its dedication to quality and compliance. (intaspharma.com) As global regulatory requirements continue to evolve, Intas's focus on quality assurance and compliance positions it favorably in the competitive pharmaceutical export market.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Imatinib shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Intas Pharmaceuticals Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
4.Verified Records: This page is backed by 27 individual customs records matching Intas Pharmaceuticals Limited exporting Imatinib, covering 18 formulations to 7 countries via 11 buyers.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 119+ countries, 456+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Imatinib

Imatinib

Intas Pharmaceuticals Limited — Imatinib Exporter Profile

Intas Pharmaceuticals Limited — Imatinib Export Profile: Buyers & Destinations

Where Does Intas Pharmaceuticals Limited Export Imatinib?

Who Are the Top Buyers of Imatinib from Intas Pharmaceuticals Limited?

What Is India's Total Imatinib Export Value and How Much Does Intas Pharmaceuticals Limited Contribute?

What Is the Average Shipment Value for Intas Pharmaceuticals Limited's Imatinib Exports?

How Does Intas Pharmaceuticals Limited Compare to Other Indian Imatinib Exporters?

What Imatinib Formulations Does Intas Pharmaceuticals Limited Export?

Regulatory Requirements: Exporting Imatinib to Key Markets

United Kingdom — MHRA

How Does Intas Pharmaceuticals Limited Compare to Nearest Imatinib Exporters?

Which Indian Ports Ship Imatinib Exports?

Geopolitical & Trade Policy Impact on Intas Pharmaceuticals Limited's Imatinib Exports

Intas Pharmaceuticals Limited — Regulatory Compliance & Quality Standards

About Intas Pharmaceuticals Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Imatinib Export Data from Intas Pharmaceuticals Limited

Imatinib Stats

Company Overview

Top Products by Intas Pharmaceuticals Limited

Related Analysis

Need Detailed Export Data?

Data Source